Pfizer will earn $15 billion from sales of its Coronavirus vaccine developed in collaboration with BioNTech.
The American pharmaceutical company forecasts $59.4 billion and $61.4 billion revenue in 2021 and expects a quarter of its total revenue this year to come from the sales of its COVID-19 vaccine.
Here is How Govt. Plans to Vaccinate All Citizens Before The End of 2021
During an interview, CEO Pfizer, Albert Bourla, said that the company is on track to produce 2 billion doses of Coronavirus vaccines this year which will see it earn $15 billion.
We’ve increased the batches we run per week, we’ve doubled the output – the yield per batch – we’ve dramatically improved our success rates, we’ve made process improvements to the assembly lines.
Govt. to Store Coronavirus Vaccine Doses at High-Security Facilities
Albert Bourla added that Pfizer could exceed the $15 billion mark if the company signs more supply contracts.
Besides, Pfizer has launched a study to determine whether a third dose of its mRNA-based Coronavirus vaccine, administered 6-12 months after the first two doses which are injected three weeks apart, can increase the immunity against the more infectious variants of Coronavirus reported across the world.